- A gross income of $250,000 or more per annum in each of the previous two financial years; or
- Net assets of at least $2.5 million; and
- A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)
Prescient Therapeutics Are Developing Game-Changing Cancer Treatments
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins ASX Investor...
Beyond Science: Future of Biotech & Healthcare: Harnessing Inventive Approaches – Kalkine Media
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins Kalkine Media...
Prescient Therapeutics AusBiotech’s Investment Conference Presentation
Prescient Therapeutics (ASX: PTX) CEO Steven Yatomi-Clarke recently presented at the AusBiotech Investment Conference 2021....
University of Pennsylvania finds solution for ‘war weary’ CAR- T cells
Researchers at the University of Pennsylvania (Penn) are developing a new way for cancer-fighting CAR-T...
Prescient Therapeutics advances innovative cancer therapies following successful FY 2021 – Small Caps
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins Small Caps...
Prescient Therapeutics Investor Replay – 10 June
Prescient Therapeutics Investor Briefing Prescient Therapeutics CEO and MD Steven Yatomi-Clarke and Senior VP of...
Prescient Therapeutics chooses three cancer programs for its next-generation CAR T platform
Melbourne-based Prescient will focus development of its OmniCAR platform into three programs: the blood cancer...
Prescient Therapeutics (ASX:PTX) to begin three next-gen CAR T programs
Prescient Therapeutics (PTX) has announced three internal development programs for its immune receptor technology platform,...
Ain’t no mountain high enough: Cancer survivor eyes Mt. Everest after revolutionary treatment
Following more than a decade of treatments, cancer survivor Laurie Adami now plans to tackle...